drug
Arexvy
Marketedupdated 4mo agoby GlaxoSmithKline Biopharmaceuticals inc
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying Arexvy
- phase2Immunogenicity of RSVPreF3 Vaccine in Immunocompromised Persons
- phase1A Study of RSV-HMPV Bivalent Vaccine VXB-241 in Older Adults
- phase1First-in-human Safety and Immunogenicity Study of SCB-1019 and SCB-1019T in Healthy Adults
- phase1Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults
- phase2RSV Vaccination in Immunocompromised Patients.
News(1)
- GSK lays off 650 staffers amid closure of German vaccine manufacturing siteGSK is consolidating its vaccine manufacturing operations to one site—located in Canada—amid the pharma’s recent $2.5 billion savings campaign.biospace · 6h ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that